Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
NCT02213289Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jan 2015
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, trastuzumab, depatuxizumab, bemarituzumab and ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Chicago. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02213289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213289.